Kenneth Zuerblis
Director/Board Member at RESVERLOGIX CORP.
Net worth: 44 077 $ as of 2024-04-29
Kenneth Zuerblis active positions
| Companies | Position | Start | End |
|---|---|---|---|
| RESVERLOGIX CORP. | Director/Board Member | 2010-09-28 | - |
| Independent Dir/Board Member | 2010-09-28 | - | |
| ZENITH CAPITAL CORP. | Director/Board Member | 2013-04-09 | - |
| Independent Dir/Board Member | 2013-04-09 | - | |
Lirum Therapeutics, Inc.
 Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Director/Board Member | 2023-04-30 | - |
Career history of Kenneth Zuerblis
Former positions of Kenneth Zuerblis
| Companies | Position | Start | End |
|---|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Director/Board Member | 2012-02-29 | 2020-06-09 |
| SAVIENT PHARMACEUTICALS INC | Director of Finance/CFO | 2011-09-11 | 2012-04-30 |
| Treasurer | 2011-09-11 | 2012-04-30 | |
| IMMUNOMEDICS, INC. | Director/Board Member | 2010-02-10 | 2012-03-07 |
| Independent Dir/Board Member | 2010-02-09 | 2012-03-07 | |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Director of Finance/CFO | 2008-12-31 | 2008-12-31 |
| XTL BIOPHARMACEUTICALS LTD. | Director/Board Member | 2008-12-31 | 2008-12-31 |
| ENZON PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 1990-12-31 | 1993-12-31 |
| Director of Finance/CFO | 1993-12-31 | 2004-12-31 | |
| ░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Kenneth Zuerblis
| Seton Hall University | Undergraduate Degree |
Statistics
International
| United States | 10 |
| Canada | 3 |
| Israel | 2 |
Operational
| Director/Board Member | 7 |
| Director of Finance/CFO | 3 |
| Independent Dir/Board Member | 3 |
Sectoral
| Health Technology | 10 |
| Commercial Services | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| RESVERLOGIX CORP. | Health Technology |
| XTL BIOPHARMACEUTICALS LTD. | Health Technology |
| ZENITH CAPITAL CORP. | Health Technology |
| Private companies | 7 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
KPMG LLP
 KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
New Jersey Technology Council
 New Jersey Technology Council Miscellaneous Commercial ServicesCommercial Services New Jersey Technology Council provides business development, education and advocacy services. It serves communications, e-business, multimedia, consumer technologies, manufacturing, engineering and energy sectors. The company was founded in 1996 and is headquartered in New Brunswick, NJ. | Commercial Services |
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Lirum Therapeutics, Inc.
Lirum Therapeutics, Inc. BiotechnologyHealth Technology Lirum Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the treatment of deliberating diseases. The firm is also involved in the acquisition, development, and commercialization of drug candidates. Its products include LX-101, a targeted therapy directed to the insulin-like growth factor 1 (IGF-1R). The company was founded in November 2021 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Kenneth Zuerblis
- Experience
